HRGNOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Harvard Apparatus Regenerative Technology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.21−0.02 (-0.72%)
Close on Oct 19, 2026
- Market cap
- $38.92M
- P/E (TTM)
- –
- Dividend yield
- –
Harvard Apparatus Regenerative Technology, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Health Products [Member] | $414.00K | $226.00K | $219.00K | $123.00K | $317.00K | $45.00K | $258.00K | $59.00K | $56.00K | $57.00K | – | 100.0% | +30.6% |
| Regenerative Biotech [Member] | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | – | 0.0% | – |
| Longevity Products [Member] | – | – | – | – | – | – | – | – | $56.00K | $57.00K | – | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Harvard Apparatus Regenerative Technology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.